Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||ALLO-647 + ALLO-715 + Cyclophosphamide + Fludarabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ALLO-647||ALLO 647|ALLO 647||ALLO-647 is a monoclonal antibody that targets CD52 (CAMPATH-1), which activates host immune response, potentially resulting in the lysis of CD52-positive tumor cells (NCI Drug Dictionary).|
|ALLO-715||ALLO715|ALLO 715||ALLO-715 consists of a preparation of allogeneic T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets BCMA, with disruption of TCR alpha and CD52 to potentially reduce risk of GVHD and resistance to CD52 antibody therapy, which may enhance cytotoxicity against tumor cells expressing BCMA (Blood (2018) 132 (Supplement 1): 591).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04093596||Phase I||ALLO-647 + ALLO-715 ALLO-647 + ALLO-715 + Cyclophosphamide + Fludarabine||Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL)||Recruiting|